High Response Rate With Neoadjuvant Anti-PD-1 in Localized dMMR Colorectal Cancer
(MedPage Today) -- Neoadjuvant immunotherapy with PD-1 inhibitors led to objective responses in 85% of patients with localized and locally advanced colorectal cancer (CRC) with mismatch repair deficiency (dMMR)/high microsatellite instability ...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Gastroenterology | Gastroschisis Repair | Immunotherapy | Neoadjuvant Therapy